Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 4Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Rheumatoid Arthritis, Systemic Juvenile 1Rectal Neoplasms 1Primary Myelofibrosis 1Periodic Fevers Syndrome 1Pancreatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Mevalonate Kinase Deficiency 1Metastatic Pancreatic Ductal Adenocarcinoma 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Intestinal Neoplasms 1Gastrointestinal Neoplasms 1Cryopyrin-Associated Periodic Syndromes 1Colorectal Neoplasms 1Colonic Neoplasms 1Clonal Cytopenia of Undetermined Significance 1Carcinoma, Renal Cell 1Carcinoma, Ductal 1Carcinoma 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1Arthritis, Juvenile 1Arthralgia 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Carboplatin 340Cisplatin 238Paclitaxel 203Radiotherapy 195Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 141Erlotinib Hydrochloride 107Etoposide 99Magnetic Resonance Spectroscopy 93Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 72durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49atezolizumab 42Irinotecan 42Radiation 40Topotecan 39Biopsy 39Standard of Care 38Cyclophosphamide 38Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × canakinumab × Clear all
NCT06038526 2026-05-20

Evaluation of Canakinumab in High-Risk Former-Smokers

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
41 enrolled
Thoracic

Lung Neoplasms

NCT04789681 2026-04-16

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
Thoracic

Lung Neoplasms

NCT05725343 2023-02-13

CANAL

Mario Negri Institute for Pharmacological Research

Phase 3 Terminated
350 enrolled
Thoracic

Lung Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔